guest ::
| Home > Publications database > 90Y-FAPI-46 Radiopharmaceutical Therapy in Sarcoma and Other Solid Tumors: An Updated Cohort Analysis. > print |
| Home > Publications database > 90Y-FAPI-46 Radiopharmaceutical Therapy in Sarcoma and Other Solid Tumors: An Updated Cohort Analysis. > print |
| 001 | 309980 | ||
| 005 | 20260220160031.0 | ||
| 024 | 7 | _ | |a 10.2967/jnumed.125.271135 |2 doi |
| 024 | 7 | _ | |a pmid:41714122 |2 pmid |
| 024 | 7 | _ | |a 0097-9058 |2 ISSN |
| 024 | 7 | _ | |a 0022-3123 |2 ISSN |
| 024 | 7 | _ | |a 0161-5505 |2 ISSN |
| 024 | 7 | _ | |a 1535-5667 |2 ISSN |
| 024 | 7 | _ | |a 2159-662X |2 ISSN |
| 037 | _ | _ | |a DKFZ-2026-00406 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Lanzafame, Helena |b 0 |
| 245 | _ | _ | |a 90Y-FAPI-46 Radiopharmaceutical Therapy in Sarcoma and Other Solid Tumors: An Updated Cohort Analysis. |
| 260 | _ | _ | |a New York, NY |c 2026 |b Soc. |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1771599618_3240620 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a epub |
| 520 | _ | _ | |a Fibroblast activation protein (FAP) is highly expressed in many cancers, especially sarcomas, and represents a promising theranostic target. We present an updated retrospective analysis of 90Y-FAP inhibitor (FAPI)-46 treatment in patients with sarcoma or other solid tumors. Methods: We performed monocentric analysis of patients with progressive sarcoma or metastatic cancer who were eligible for 90Y-FAPI-46 therapy after approved treatments had been exhausted and who showed high FAP expression (SUVmax, ≥10 in over 50% of lesions on 68Ga-FAPI-46 PET). After therapy, 90Y-FAPI-46 scintigraphy confirmed distribution and uptake, and serial 90Y-FAPI-46 PET/CT scans measured absorbed doses. Adverse events were graded by Common Terminology Criteria for Adverse Events version 5.0. Tumor responses were evaluated using RECIST and PERCIST. Results: Thirty patients-23 (77%) with sarcoma, 3 (10%) with pancreatic cancer, 1 (3%) with prostate cancer, 1 (3%) with gastric cancer, 1 (3%) with nonmelanoma skin cancer, and 1 (3%) with cholangiocarcinoma-received a total of 77 cycles of 90Y-FAPI-46 radiopharmaceutical therapy between June 2020 and December 2023 and were followed until death or the last follow-up (April 2024). The median interval between cycles was 5 mo (interquartile range [IQR], 4 mo). Of the 30 patients, 11 (37%) received 4 or more cycles. A median of 3.7 GBq (IQR, 3.7-3.8 GBq) was administered during the first cycle, and a median of 7.4 GBq (IQR, 7.2-7.4 GBq) was administered for subsequent cycles. The mean absorbed dose was 0.48 Gy/GBq (SD, 0.06 Gy/GBq) in the kidneys and 0.04 Gy/GBq (SD, 0.01 Gy/GBq) in the bone marrow. Lesions with the highest uptake absorbed a mean dose of 2.4 Gy/GBq (SD, 1.04 Gy/GBq). After treatment, hematotoxicity of any grade was observed in 20 of 30 (67%) patients. Eight of 30 (27%) patients reached a Common Terminology Criteria for Adverse Events grade of at least 3, experiencing adverse events that included thrombocytopenia in 2 (6%), neutropenia in 2 (6%), anemia in 2 (6%), leukopenia in 1 (3%), and elevated γ-glutamyl transferase in 1 (3%) patient. RECIST (n = 25) and PERCIST (n = 20) responses after treatment were assessed. Disease control according to RECIST was 48% (12/25), including 3 partial responses (12%). Disease control correlated with extended overall survival (median, 14.6 vs. 1.9 mo). Metabolic response per PERCIST was observed in 12 of 20 (60%) patients. Conclusion: With long-term follow-up, the favorable safety profile of 90Y-FAPI-46 therapy is confirmed. Nearly half of the patients demonstrated disease stabilization, almost exclusively in sarcomas. Our findings support the role of FAP-directed radiopharmaceutical therapy in patients with metastatic sarcoma. |
| 536 | _ | _ | |a 312 - Funktionelle und strukturelle Genomforschung (POF4-312) |0 G:(DE-HGF)POF4-312 |c POF4-312 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a 90Y-FAPI-46 |2 Other |
| 650 | _ | 7 | |a radiopharmaceutical therapy |2 Other |
| 650 | _ | 7 | |a sarcomas |2 Other |
| 650 | _ | 7 | |a theranostics |2 Other |
| 700 | 1 | _ | |a Mavroeidi, Ilektra A |b 1 |
| 700 | 1 | _ | |a Pabst, Kim M |b 2 |
| 700 | 1 | _ | |a Fragoso Costa, Pedro |b 3 |
| 700 | 1 | _ | |a Schuler, Martin |b 4 |
| 700 | 1 | _ | |a Bauer, Sebastian |b 5 |
| 700 | 1 | _ | |a Kurth, Jens |b 6 |
| 700 | 1 | _ | |a Heuschkel, Martin |b 7 |
| 700 | 1 | _ | |a Siveke, Jens T |0 P:(DE-He78)026e0a55b968f360a3c349689ce8a99c |b 8 |u dkfz |
| 700 | 1 | _ | |a Herrmann, Ken |b 9 |
| 700 | 1 | _ | |a Kostbade, Karina |b 10 |
| 700 | 1 | _ | |a Kersting, David |b 11 |
| 700 | 1 | _ | |a Leyser, Stephan |b 12 |
| 700 | 1 | _ | |a Fröhling, Stefan |0 P:(DE-He78)f0144d171d26dbedb67c9db1df35629d |b 13 |
| 700 | 1 | _ | |a Heilig, Christoph E |0 P:(DE-He78)42b6114cd48e033299b2b6ef4bf56cc6 |b 14 |u dkfz |
| 700 | 1 | _ | |a Hamacher, Rainer |b 15 |
| 700 | 1 | _ | |a Fendler, Wolfgang P |b 16 |
| 773 | _ | _ | |a 10.2967/jnumed.125.271135 |g p. jnumed.125.271135 - |0 PERI:(DE-600)2040222-3 |p nn |t Journal of nuclear medicine |v nn |y 2026 |x 0097-9058 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 8 |6 P:(DE-He78)026e0a55b968f360a3c349689ce8a99c |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 13 |6 P:(DE-He78)f0144d171d26dbedb67c9db1df35629d |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 14 |6 P:(DE-He78)42b6114cd48e033299b2b6ef4bf56cc6 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-312 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Funktionelle und strukturelle Genomforschung |x 0 |
| 914 | 1 | _ | |y 2026 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2025-11-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2025-11-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0320 |2 StatID |b PubMed Central |d 2025-11-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2025-11-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2025-11-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2025-11-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2025-11-10 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2025-11-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2025-11-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2025-11-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2025-11-10 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b J NUCL MED : 2022 |d 2025-11-10 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b J NUCL MED : 2022 |d 2025-11-10 |
| 920 | 1 | _ | |0 I:(DE-He78)ED01-20160331 |k ED01 |l DKTK Koordinierungsstelle Essen/Düsseldorf |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)B340-20160331 |k B340 |l Translationale Medizinische Onkologie |x 1 |
| 920 | 1 | _ | |0 I:(DE-He78)HD01-20160331 |k HD01 |l DKTK HD zentral |x 2 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)ED01-20160331 |
| 980 | _ | _ | |a I:(DE-He78)B340-20160331 |
| 980 | _ | _ | |a I:(DE-He78)HD01-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|